当前位置: 首页 >> 检索结果
362. Causes of death in people with coeliac disease in England compared with the general population: a competing risk analysis.
作者: Alyshah Abdul Sultan.;Colin J Crooks.;Tim Card.;Laila J Tata.;Kate M Fleming.;Joe West.
来源: Gut. 2015年64卷8期1220-6页
Quantifying excess cause-specific mortality among people with coeliac disease (CD) compared with the general population accounting for competing risks will allow accurate information to be given on risk of death from specific causes.
364. A rare cause of abdominal pain, diarrhoea and GI bleeding. Idiopathic myointimal hyperplasia of the mesenteric veins (IMHMV).
作者: Faidon-Marios Laskaratos.;Mark Hamilton.;Marco Novelli.;Neil Shepherd.;Gareth Jones.;Christopher Lawrence.;Miriam Mitchison.;Charles D Murray.
来源: Gut. 2015年64卷2期214, 350页 365. The relationship between infliximab concentrations, antibodies to infliximab and disease activity in Crohn's disease.
作者: Niels Vande Casteele.;Reena Khanna.;Barrett G Levesque.;Larry Stitt.;G Y Zou.;Sharat Singh.;Steve Lockton.;Scott Hauenstein.;Linda Ohrmund.;Gordon R Greenberg.;Paul J Rutgeerts.;Ann Gils.;William J Sandborn.;Séverine Vermeire.;Brian G Feagan.
来源: Gut. 2015年64卷10期1539-45页
Although low infliximab trough concentrations and antibodies to infliximab (ATI) are associated with poor outcomes in patients with Crohn's disease (CD), the clinical relevance of ATI in patients with adequate infliximab concentrations is uncertain. We evaluated this question using an assay sensitive for identification of ATI in the presence of infliximab.
366. SOX9 regulates ERBB signalling in pancreatic cancer development.
作者: Adrien Grimont.;Andreia V Pinho.;Mark J Cowley.;Cécile Augereau.;Amanda Mawson.;Marc Giry-Laterrière.;Géraldine Van den Steen.;Nicola Waddell.;Marina Pajic.;Christine Sempoux.;Jianmin Wu.;Sean M Grimmond.;Andrew V Biankin.;Frédéric P Lemaigre.;Ilse Rooman.;Patrick Jacquemin.
来源: Gut. 2015年64卷11期1790-9页
The transcription factor SOX9 was recently shown to stimulate ductal gene expression in pancreatic acinar-to-ductal metaplasia and to accelerate development of premalignant lesions preceding pancreatic ductal adenocarcinoma (PDAC). Here, we investigate how SOX9 operates in pancreatic tumourigenesis.
373. Global incidence of oesophageal cancer by histological subtype in 2012.
The two major histological types of oesophageal cancer--adenocarcinoma (AC) and squamous cell carcinoma (SCC)--are known to differ greatly in terms of risk factors and epidemiology. To date, global incidence estimates for individual subtypes are still lacking. This study for the first time quantified the global burden of oesophageal cancer by histological subtype.
374. Acute kidney injury and acute-on-chronic liver failure classifications in prognosis assessment of patients with acute decompensation of cirrhosis.
作者: Paolo Angeli.;Ezequiel Rodríguez.;Salvatore Piano.;Xavier Ariza.;Filippo Morando.;Elsa Solà.;Antonietta Romano.;Elisabet García.;Marco Pavesi.;Alessandro Risso.;Alexander Gerbes.;Chris Willars.;Mauro Bernardi.;Vicente Arroyo.;Pere Ginès.; .
来源: Gut. 2015年64卷10期1616-22页
Prognostic stratification of patients with cirrhosis is common clinical practice. This study compares the prognostic accuracy (28-day and 90-day transplant-free mortality) of the acute-on-chronic liver failure (ACLF) classification (no ACLF, ACLF grades 1, 2 and 3) with that of acute kidney injury (AKI) classification (no AKI, AKI stages 1, 2 and 3).
375. Authors' response to the letter: Liver resection for patients with hepatocellular carcinoma and macrovascular invasion, multiple tumours or portal hypertension by Zhong et al.376. Cost-effectiveness analysis of sofosbuvir-based regimens for chronic hepatitis C.
作者: Ramón San Miguel.;Vicente Gimeno-Ballester.;Antonio Blázquez.;Javier Mar.
来源: Gut. 2015年64卷8期1277-88页
A new scenario of therapy for chronic hepatitis C (CHC) is being established with the approval of sofosbuvir (SOF).
377. Tralokinumab for moderate-to-severe UC: a randomised, double-blind, placebo-controlled, phase IIa study.
作者: Silvio Danese.;Janusz Rudziński.;Wolfgang Brandt.;Jean-Louis Dupas.;Laurent Peyrin-Biroulet.;Yoram Bouhnik.;Dariusz Kleczkowski.;Peter Uebel.;Milan Lukas.;Mikael Knutsson.;Fredrik Erlandsson.;Mark Berner Hansen.;Satish Keshav.
来源: Gut. 2015年64卷2期243-9页
Interleukin-13 (IL-13) has been implicated as a key driver of UC. This trial evaluates the efficacy and safety of tralokinumab, an IL-13-neutralising antibody, as add-on therapy in adults with moderate-to-severe UC despite standard treatments.
378. Scheduled second-look endoscopy is not recommended after endoscopic submucosal dissection for gastric neoplasms (the SAFE trial): a multicentre prospective randomised controlled non-inferiority trial.
作者: Satoshi Mochizuki.;Noriya Uedo.;Ichiro Oda.;Kazuhiro Kaneko.;Yorimasa Yamamoto.;Takeshi Yamashina.;Haruhisa Suzuki.;Shinya Kodashima.;Tomonori Yano.;Nobutake Yamamichi.;Osamu Goto.;Takeshi Shimamoto.;Mitsuhiro Fujishiro.;Kazuhiko Koike.; .
来源: Gut. 2015年64卷3期397-405页
To clarify the effectiveness of second-look endoscopy (SLE) at preventing bleeding after gastric endoscopic submucosal dissection (ESD).
379. Interferon gamma receptor 2 gene variants are associated with liver fibrosis in the general population: the Rotterdam Study.
作者: Elisabeth P C Plompen.;Bettina E Hansen.;Jeoffrey N L Schouten.;Sarwa Darwish Murad.;Daan W Loth.;Willem Pieter Brouwer.;Aaron Isaacs.;Pavel Taimr.;Albert Hofman.;Cornelia M van Duijn.;André G Uitterlinden.;Bruno H C Stricker.;Frank W G Leebeek.;Harry L A Janssen.
来源: Gut. 2015年64卷4期692-4页 |